在胰腺癌中,KRAS抑制激活了可操作的CD24"不要吃我"信号
Yongkun Wei1, Minghui Liu1, Er-Yen Yen2,3
1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer research
|September 18, 2025
概括
KRASG12C 抑制剂在胰腺癌中显示出有限的益处. 阻止CD24的"不要吃我"信号增强了免疫细胞对癌细胞的向,提高了KRAS驱动的胰腺管道腺癌的治疗疗效.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 克拉斯格12C抑制剂在胰腺管道腺癌 (PDAC) 中提供了适度的临床益处.
- 了解和克服对KRASG12C抑制剂的耐药性机制对于改善患者的治疗结果至关重要.
- 开发本土模型是研究KRAS驱动的PDAC生物学和治疗耐药性的关键.
研究的目的:
- 研究KRASG12C的生物功能,并确定PDAC中的绕道机制.
- 在相关的临床前模型中评估KRASG12C抑制剂的疗效.
- 发现适应性抵抗机制和潜在的治疗点.
主要方法:
- 开发一种本土的KRASG12C驱动的PDAC小鼠模型.
- 与KRASG12D驱动的PDAC模型进行比较.
- 用KRASG12C抑制剂治疗和随后的免疫制.
- 评估CD24表达和阻断对瘤免疫和反应的影响.
主要成果:
- 克拉斯格12C模型的瘤生长速度较慢,但与克拉斯格12D模型的特征相似.
- 克拉斯格12C抑制剂诱导了"热"的瘤免疫微环境,临床影响不大.
- CD24,一个"不要吃我"信号,在治疗后的癌细胞上升调节.
- 在KRASG12C和KRASG12D模型中,CD24阻塞增强了巨细胞化,并使瘤对G12Ci治疗敏感.
结论:
- 这项研究揭示了PDAC中独特的KRAS等位基特异性生物学.
- CD24的升级代表了一种临床可行的适应性抵抗机制.
- 向CD24与KRAS抑制剂相结合可能会提高PDAC的治疗疗效.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
19.1K
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.5K
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
5.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.4K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
